Maham Fatima
2 min read
In This Article:
On Friday, BofA increased its price target for Merus (NASDAQ:MRUS) to $92 from $70, while maintaining a Buy rating on the stock.
The decision follows Merus' highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating first-line head and neck squamous cell carcinoma/HNSCC. The trial achieved a 12-month objective survival rate of 79% in its full cohort.
A microscope with biomedical samples, highlighting the research efforts of the company.
The survival rate surpasses historical benchmarks for pembrolizumab monotherapy, which typically range from 50% to 59% in the same patient population. It also well exceeds the 50%-60% range that BofA's medical checks had indicated would constitute good data. BofA believes that the data positions the peto + pembr combination as a potentially best-in-class treatment option for patients with HNSCC.
The promising interim data from the Phase 2 trial, revealed at the ASCO Annual Meeting, showed a 63% overall response rate among 43 evaluable patients, which included 6 complete responses and 21 partial responses. The median progression-free survival was 9 months, and responses were observed across various PD-L1 levels, with 14 responding patients still on treatment at the data cutoff.
Merus (NASDAQ:MRUS) is a clinical-stage immuno-oncology company that primarily develops antibody therapeutics in the Netherlands.
While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
